Aplastic Anemia and Related Bone Marrow Failure States

[1]  A. Risitano.  Immunosuppressive therapies in the management of immune‐mediated marrow failures in adults: where we stand and where we are going , 2011, British journal of haematology.

[2]  Jianxiang Wang,et al.  Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience , 2011, Annals of Hematology.

[3]  O. Shpilberg,et al.  Management of Aplastic Anemia: The Role of Systematic Reviews and Meta-Analyses , 2010, Acta Haematologica.

[4]  J. G. van den Tweel,et al.  The pathology of bone marrow failure , 2010, Histopathology.

[5]  S. Park,et al.  Clinical course of non-severe aplastic anemia in adults , 2010, International journal of hematology.

[6]  A. Risitano,et al.  Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) , 2010, Haematologica.

[7]  I. Macdougall,et al.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. , 2009, The New England journal of medicine.

[8]  M. Aljurf,et al.  Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen , 2009, Haematologica.

[9]  A. Auerbach,et al.  Fanconi anemia and its diagnosis. , 2009, Mutation research.

[10]  L. Vidal,et al.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis , 2009, Haematologica.

[11]  J. Passweg,et al.  Diagnosis and treatment of acquired aplastic anemia. , 2009, Hematology/oncology clinics of North America.

[12]  S. Ellis,et al.  Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. , 2009, Hematology/oncology clinics of North America.

[13]  G. Bagby,et al.  Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention. , 2009, Hematology/oncology clinics of North America.

[14]  J. Soulier,et al.  Diagnosis of Fanconi anemia in patients with bone marrow failure , 2009, Haematologica.

[15]  O. Shpilberg,et al.  ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia – Systematic Review and Meta-Analysis , 2009, Acta Haematologica.

[16]  Masuji Yamamoto,et al.  Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia , 2007, Haematologica.

[17]  S. Chanock,et al.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. , 2007, Blood.

[18]  J. Klein,et al.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. , 2007, Blood.

[19]  G. Cook,et al.  A third course of anti‐thymocyte globulin in aplastic anaemia is only beneficial in previous responders , 2005, British journal of haematology.

[20]  J. Wagner,et al.  Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. , 2004, Blood.

[21]  H. Cannell.  Dyskeratosis congenita. , 1971, The British journal of oral surgery.